International Journal of Radiation Oncology * Biology * Physics
Volume 65, Issue 5 , Pages 1330-1337 , 1 August 2006

Double-blinded, placebo-controlled trial on intravenous l-alanyl-l-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer

The present work was, in part, presented and awarded at the 17th International Symposium of the Multinational Association of Supportive Care in Cancer, Geneva, Switzerland on 2005; and in the First International Congress of the Latin American and Caribbean Society of Oncology, Buenos Aires, Argentina on 2005.

  • Leandro C.A. Cerchietti, M.D.

      Affiliations

    • Translational Research Unit, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina
    • Corresponding Author InformationReprint requests to: Leandro C. A. Cerchietti, M.D., Albert Einstein College of Medicine, 1300 Morris Park Ave., Chanin Building, Room 517, Bronx, NY 10461. Tel: (718) 430-4239; Fax: (718) 430-8567
    • ,
  • Alfredo H. Navigante, M.D., Ph.D.

      Affiliations

    • Translational Research Unit, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina
    • Internal Medicine Department, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina
    • ,
  • Maribel A. Lutteral, M.D.

      Affiliations

    • Internal Medicine Department, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina
    • ,
  • Monica A. Castro, M.D.

      Affiliations

    • Translational Research Unit, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina
    • ,
  • Ricardo Kirchuk, M.D.

      Affiliations

    • Internal Medicine Department, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina
    • ,
  • Marcelo Bonomi, M.D.

      Affiliations

    • Translational Research Unit, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina
    • Radiotherapy Department, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina
    • ,
  • Maria Esther Cabalar, M.D.

      Affiliations

    • Internal Medicine Department, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina
    • ,
  • Berta Roth, M.D.

      Affiliations

    • Radiotherapy Department, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina
    • ,
  • Graciela Negretti, Pharm.D.

      Affiliations

    • Pharmacy Department, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina
    • ,
  • Beatriz Sheinker, Pharm.D.

      Affiliations

    • Pharmacy Department, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina
    • ,
  • Patricia Uchima, Pharm.D.

      Affiliations

    • Pharmacy Department, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina

Received 23 November 2005 ,Revised 27 February 2006 ,Accepted 12 March 2006.

References 

  1. Seiwert T , Cohen E . State-of-the-art management of locally advanced head and neck cancer . Br J Cancer . 2005;92:1341–1348
  2. Vermorken J . Medical treatment in head and neck cancer . Ann Oncol . 2005;16:ii258–ii264
  3. Merlano M , Marchetti G . Radiochemotherapy in head and neck cancer . Cancer Treat Rev . 2003;29:291–296
  4. Brizel D , Albers M , Fischer S , et al.   Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer . N Engl J Med . 1998;338:1798–1804
  5. Trotti A , Bellm L , Epstein J , et al.   Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy (A systematic literature review) . Radiother Oncol . 2003;66:253–262
  6. Giglio R , Mickiewicz E , Pradier R , et al.   Sustained high complete response with an intensive treatment of concurrent chemoradiotherapy for oropharynx cancer [abstract] . J Clin Oncol . 2002;21:238a; ASCO Annual Meeting Proceedings
  7. Duncan M , Grant G . Review article (Oral and intestinal mucositis—causes and possible treatments) . Aliment Pharmacol Ther . 2003;18:853–874
  8. Lacey J , Wilmore D . Is glutamine a conditionally essential amino acid? . Nutr Rev . 1990;48:297–309
  9. Kubota A , Meguid M , Hitch D . Amino acid profiles correlate diagnostically with organ site in three kinds of malignant tumors . Cancer . 1992;69:2343–2348
  10. Neu J , DeMarco V , Li N . Glutamine (Clinical applications and mechanisms of action) . Curr Opin Clin Nutr Metab Care . 2002;5:69–75
  11. Savarese D , Savy G , Vahdat L , et al.   Prevention of chemotherapy and radiation toxicity with glutamine . Cancer Treat Rev . 2003;29:501–513
  12. Albert S , Wernerman J , Stehle P , et al.   Availability of amino acids supplied intravenously in healthy man as synthetic dipeptides (Kinetic evaluation of l-alanyl-l-glutamine and glycyl-l-tyrosine) . Clin Sci . 1988;75:463–468
  13. Bai M , Jiang Z , Liu Y , et al.   Effects of alanyl-glutamine on gut barrier function . Nutrition . 1996;12:793–796
  14. Decker-Baumann C , Buhl K , Frohmuller S , et al.   Reduction of chemotherapy-induced side-effects by parental glutamine supplementation in patients with metastatic colorectal cancer . Eur J Cancer . 1999;35:202–207
  15. World Health Organization . In: Handbook for reporting results of cancer treatment . Geneva, Switzerland: WHO; 1979;p. 15–22
  16. Sonis S , Eilers J , Epstein J , et al.   Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy . Cancer Treat Rev . 1999;85:2103–2113
  17. Oken M , Creech R , Tormey D , et al.   Toxicity and response criteria of the Eastern Cooperative Oncology Group . Am J Clin Oncol . 1982;5:649–655
  18. Huang E , Wan Leung S , Wang C , et al.   Oral glutamine to alleviate radiation-induced oral mucositis (A pilot randomized trial) . Int J Radiat Oncol Biol Phys . 2000;46:535–539
  19. Anderson P , Schroeder G , Skubitz K . Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy . Cancer . 1998;83:1433–1439
  20. Okuno S , Woodhouse C , Loprinzi C , et al.   Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy . Am J Clin Oncol . 1999;22:258–261
  21. Jebb S , Osborne R , Maughan T , et al.   5-fluorouracil and folinic acid-induced mucositis (No effect of oral glutamine supplementation) . Br J Cancer . 1994;70:732–735
  22. Curi R , Lagranha C , Doi S , et al.   Molecular mechanisms of glutamine action . J Cell Physiol . 2005;204:392–401
  23. Sonis S . The pathobiology of mucositis . Nature Rev Cancer . 2004;4:277–284
  24. Carneiro-Filho B , Oria R , Wood Rea K , et al.   Alanyl-glutamine hastens morphologic recovery from 5-fluorouracil-induced mucositis in mice . Nutrition . 2004;20:934–941
  25. Chen MK , Salloum RM , Austgen TR , et al.   Tumor regulation of hepatic glutamine metabolism . J Parenter Enteral Nutr . 1991;15:159–164
  26. Erickson R , Ross D , Medina J . Effects of glutamine on head and neck squamous cell carcinoma . Otolaryngol Head Neck Surg . 1999;121:348–354
  27. Rouse K , Nwokedi E , Woodliff J , et al.   Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism . Ann Surg . 1995;221:420–426

 Collaborators to this study: Professor Dr. Roberto Pradier, Dr. Raul Giglio, Mrs. Viviana Candlish, Mrs. Elsa Gomez, RN (all from the Instituto Angel Roffo), Mr. Raul Honig, Dr. Graciela Merino, and Dr. Mario Perman.

PII: S0360-3016(06)00576-1

doi: 10.1016/j.ijrobp.2006.03.042

International Journal of Radiation Oncology * Biology * Physics
Volume 65, Issue 5 , Pages 1330-1337 , 1 August 2006

Article Tools

* Image Usage & Resolution